NCT07207408View on ClinicalTrials.gov

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

May 29, 2026

Study Completion Date

October 16, 2026

Conditions
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
Interventions
BIOLOGICAL

rF1V-1018

Regimen 1

BIOLOGICAL

rF1V-1018

Regimen 2

BIOLOGICAL

rF1V-1018

Regimen 3

BIOLOGICAL

rF1V-1018

Regimen 4

BIOLOGICAL

rF1V-1018

Regimen 5

BIOLOGICAL

rF1V-1018

Regimen 6

Trial Locations (3)

33134

NOT_YET_RECRUITING

AMR- Miami, Miami

67042

RECRUITING

AMR- El Dorado, El Dorado

889119

RECRUITING

AMR- Las Vegas, Las Vegas

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Dynavax Technologies Corporation

INDUSTRY

NCT07207408 - Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Biotech Hunter | Biotech Hunter